Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Allakos Inc.    ALLK

ALLAKOS INC.

(ALLK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Allakos Inc.
Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.

Number of employees : 90 people.
Managers
NameAgeSinceTitle
Robert Alexander492019Chief Executive Officer & Director
Adam Tomasi492019President & Chief Operating Officer
Dan Janney532017Chairman
Leo J. Redmond-2019Chief Financial & Accounting Officer
Henrik Sandvad Rasmussen, Dr.602017Chief Medical Officer
Ruby Casareno, Dr.--Vice President-Technical Operations
John P. McKearn, Dr.652012Independent Director
Steven P. James602016Independent Director
Paul E. Walker442017Independent Director
Robert E. Andreatta572018Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 52,503,346 47,531,431 90.5% 0 0.0% 90.5%
Shareholders
NameEquities%
Alta Partners Management Corp. 10,549,113 20.3%
Capital Research & Management Co. (World Investors) 5,794,660 11.2%
RiverVest Venture Management LLC 5,750,506 11.1%
Capital Research & Management Co. (Global Investors) 5,737,686 11.0%
Bayer Aktiengesellschaft 4,545,723 8.75%
Capital Research & Management Co. (International Investors) 3,585,500 6.90%
Redmile Group LLC 2,619,080 5.04%
The Vanguard Group, Inc. 2,560,094 4.93%
NEA Management Co. LLC 2,268,188 4.37%
SSgA Funds Management, Inc. 988,283 1.90%
Company contact information
Allakos, Inc.
975 Island Drive
Suite 201
Redwood City, CA 94065

Phone : +1.650.597.5002
Web : http://www.allakos.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ALLAKOS INC.8.78%5 446
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273
GENMAB A/S55.72%24 142
BEIGENE, LTD.59.36%24 079
ARGENX SE59.89%12 942
MYOKARDIA, INC.208.58%11 993
MIRATI THERAPEUTICS, INC.74.97%11 336
HUALAN BIOLOGICAL ENGINEERING INC.49.79%11 237
SAREPTA THERAPEUTICS, INC.5.18%10 710
NEUROCRINE BIOSCIENCES, INC.-11.51%8 887
ASCENDIS PHARMA A/S16.55%8 661
ULTRAGENYX PHARMACEUTICAL INC.180.57%7 927
DENALI THERAPEUTICS INC.247.99%7 269
ACCELERON PHARMA INC.114.54%6 854
BIOCON LIMITED44.96%6 836
KODIAK SCIENCES INC.83.74%6 659
PEPTIDREAM INC.-10.36%6 053